<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994773</url>
  </required_header>
  <id_info>
    <org_study_id>HBV 14934</org_study_id>
    <secondary_id>Simvastatin against HepB</secondary_id>
    <nct_id>NCT00994773</nct_id>
  </id_info>
  <brief_title>Simvastatin for the Treatment of Chronic Hepatitis B</brief_title>
  <official_title>A Pilot Trial of Simvastatin Alone and Added to Tenofovir or Entecavir for the Treatment of Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bader, Ted, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bader, Ted, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have shown robust in vitro anti-hepatitis B activity of simvastatin alone
      and synergistic activity with all four FDA-approved anti-hepatitis B oral drugs tested. The
      investigators propose phase 1 studies in 48 chronic hepatitis B human carriers who have never
      been treated before. Doses of drugs will remain at or below FDA-approved dosage levels for
      cholesterol lowering (simvastatin) or hepatitis B (tenofovir or entecavir). Arm 1 will have
      simvastatin monotherapy only. Arm 2 will combine simvastatin with tenofovir. Arm 3 will
      combine simvastatin with entecavir. For maximum safety, the 3 arms and the dose groups in
      each arm will be filled consecutively and not concurrently. The definition of efficacy for
      simvastatin alone will be a 1 log drop of hepatitis B virus in 14 days. Efficacy for
      combination of drugs will require a 2 log drop of hepatitis B virus in 14 days. Numerous
      safety tests and stop rules are noted in the protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of HBV DNA by one log.</measure>
    <time_frame>14 days</time_frame>
    <description>Simvastatin will be given in doses of 5,10,20,and 40mg per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT) reduction</measure>
    <time_frame>14 days</time_frame>
    <description>ALT changes will be noted</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin and tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin combined with tenofovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin and entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin combined with entecavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>daily doses for 14 days</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin and tenofovir</arm_group_label>
    <arm_group_label>Simvastatin and entecavir</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <arm_group_label>Simvastatin and tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir</description>
    <arm_group_label>Simvastatin and entecavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hepatitis B positive by HBV DNA within 180 days.

          2. Ages 18-70.

          3. Men and non-pregnant women eligible.

          4. Veteran's eligibility or appropriate health insurance.

        Exclusion Criteria:

          1. Use of any anti-HBV medicine within 30 days.

          2. Decompensated cirrhosis as evidenced by esophageal varices, ascites, or
             encephalopathy. (grade 1 varices without history of bleeding will be allowed, if
             patient meets Child's-Pugh functional classification grade A).

          3. A positive urine test for marijuana or alcohol within 2 months of screening.(Allowed
             to repeat tests on different days, if positive first time in order to become eligible
             for study.

          4. Severe cardiovascular disease (ejection fraction &lt;20%)* or uncontrolled angina.

          5. Severe pulmonary disease (FEV1 &lt; 1.0).

          6. Chronic renal insufficiency (creatinine clearance &lt;50 ml/min.

          7. HIV positive patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teddy Bader, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>August 15, 2012</last_update_submitted>
  <last_update_submitted_qc>August 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bader, Ted, M.D.</investigator_affiliation>
    <investigator_full_name>Ted Bader, MD</investigator_full_name>
    <investigator_title>Director of Liver Diseases, OUHSC/VAMC</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>simvastatin</keyword>
  <keyword>HBV DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

